Clinical trial
Open access
Oct 2026
Blood‐based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG‐GY012
The NRG‐GY012 phase 2 trial evaluated olaparib, cediranib, and the combination in 120 patients with recurrent, persistent, or metastatic endometrial cancer (EC). Predictive and prognostic associations between blood‐based biomarkers and clinical outcomes were assessed.
Andrew B. Nixon, Danielle M. Enserro, D. Bender et al.
· Cancer · 0 citations